Rinri Therapeutics starts transformational year at JP Morgan conference, discussing upcoming first-in-human trial in neural hearing loss
Sheffield, UK, January 14 2025 – Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, is starting an important year for the company with attendance at the 43rd JP Morgan Healthcare Conference. CEO Dr Simon Chandler and Chairman David Hipkiss will be discussing the first-in-human trial for Rincell-1, the company’s lead first-in-class product for neural hearing loss, which is expected to start in 2025. The £20m Series A financing round which is underway will fund development of Rincell-1 through to clinical proof-of-concept, a point of significant value creation.
Rincell-1 is designed to address neural hearing loss by regenerating the auditory nerves in the cochlea that connect the inner ear and the brain. It is expected to provide a novel disease-modifying treatment for patients with severe-to-profound age-related hearing loss (presbycusis) and post-synaptic auditory neuropathy, which together affect over 100m people worldwide.
Rincell-1 was developed using the pioneering OSPREY™ platform for generating allogeneic “off-the-shelf” regenerative cell therapies for neural hearing loss. It has achieved outstanding preclinical safety and efficacy data with a clinical-grade product. Rinri Therapeutics recently announced1 details of the novel procedure for cell delivery to be used in the first-in-human trial of Rincell-1, which provides a less invasive and more accessible approach compared with current technologies for access to the cochlear nerve. Rinri Therapeutics expects to file this data to secure a CTA from the UK Medicines and Healthcare products Regulatory Agency in H1 2025.
Dr Simon Chandler, CEO of Rinri Therapeutics, said:
This is expected to be an exciting year for the company with the first-in-human trial for our lead product on track to start, bringing the potential to transform the lives of people with neural hearing loss and play a role in healthy aging. Rinri Therapeutics is pleased to be at the JP Morgan conference to make connections with investors and partners.
